Routine board expansion with experienced pharma executives — no immediate catalyst. Monitor for any strategic or pipeline announcements that may follow the addition of these directors.
Price Chart
Executive Summary
Mineralys Therapeutics appointed Kristine Peterson and Lonnel Coats to its Board of Directors, expanding the board from seven to nine members. Both new directors received standard initial equity grants (options for 16,600 shares and RSUs for 12,400 shares each) under the company's non-employee director compensation program. This is a routine governance filing with no material financial impact.
Key Facts
- Board expanded from seven to nine directors with the appointment of Kristine Peterson and Lonnel Coats, effective October 19, 2026.
- Peterson appointed as Class I director (term expiring at 2027 annual meeting) and member of Audit Committee.
- Coats appointed as Class II director (term expiring at 2028 annual meeting) and member of Compensation Committee.
- Each new director received an option to purchase 16,600 shares and an RSU award covering 12,400 shares, both vesting over three years.
- Both directors deemed independent under Nasdaq rules.
Financial Impact
Standard initial equity grants for two non-employee directors — no material financial impact.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001933414-26-000125 |
| Document: 0001933414-26-000125-index-headers.html | 0001933414-26-000125 |
| Document: 0001933414-26-000125-index.html | 0001933414-26-000125 |
| Document: 0001933414-26-000125.txt | 0001933414-26-000125 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 3 | $21.10 | awaiting T+20 | awaiting T+20 | $21.13 (+0.14%) |
Oct 20, 2026 7d ago | 3 | $21.10 | awaiting T+20 | awaiting T+20 | $21.13 (+0.14%) |
Oct 19, 2026 8d ago | 8-K | $21.58 | awaiting T+20 | awaiting T+20 | $21.13 (−2.09%) |
Oct 13, 2026 14d ago | 144 | $20.76 | awaiting T+20 | awaiting T+20 | $21.13 (+1.78%) |
Sep 30, 2026 27d ago | 144 | $23.72 | awaiting T+20 | awaiting T+20 | $21.13 (−10.92%) |
Sep 29, 2026 28d ago | Press Release | $25.13 | awaiting T+20 | awaiting T+20 | $21.13 (−15.92%) |
Sep 24, 2026 4w ago | Insider Cluster | $25.86 $20.55 | ▲ +20.53% | ▲ +19.06% | $21.13 (+18.29%) |
Sep 22, 2026 5w ago | Insider Cluster | $26.89 $21.10 | ▼ −21.53% | ▼ −22.22% | $21.13 (−21.42%) |
Aug 12, 2026 10w ago | 3 | $26.09 $28.20 | ▲ +8.09% | ▲ +9.83% | $21.13 (−19.01%) |
Jul 23, 2026 13w ago | Insider Cluster | $26.71 $25.65 | ▼ −3.97% | ▼ −7.59% | $21.13 (−20.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers